表紙
市場調査レポート

B細胞非ホジキンリンパ腫:パイプライン製品の分析

B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 251598
出版日 ページ情報 英文 1066 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
B細胞非ホジキンリンパ腫:パイプライン製品の分析 B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2016
出版日: 2016年04月30日 ページ情報: 英文 1066 Pages
概要

非ホジキンリンパ腫(NHL)は、体の免疫系の一部である、リンパ球と呼ばれる細胞から発症する癌です。リンパ球の2大タイプは、Bリンパ球(B細胞)とTリンパ球(T細胞)です。BBリンパ球(B細胞)に由来する癌が、B細胞非ホジキンリンパ腫です。一般的な兆候と症状は、リンパ節の腫大(痛みがある場合も)、発熱、寝汗、原因不明の体重減少、活力不足などが挙げられます。治療は、外科手術、放射線療法、化学療法などが行われます。

当レポートでは、B細胞非ホジキンリンパ腫に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

  • イントロダクション
  • B-Cell Non-Hodgkin Lymphomaの概要
  • 治療薬の開発
  • B-Cell Non-Hodgkin Lymphoma:企業で開発中の治療薬
  • B-Cell Non-Hodgkin Lymphoma:大学/機関で研究中の治療薬
  • B-Cell Non-Hodgkin Lymphoma:パイプライン製品の概況
  • B-Cell Non-Hodgkin Lymphoma:企業で開発中の製品
  • B-Cell Non-Hodgkin Lymphoma:大学/機関で研究中の製品
  • B-Cell Non-Hodgkin Lymphomaの治療薬開発に従事している企業
  • B-Cell Non-Hodgkin Lymphoma:治療薬の評価
  • 薬剤プロファイル
  • B-Cell Non-Hodgkin Lymphoma:最近のパイプライン動向
  • B-Cell Non-Hodgkin Lymphoma:休止中のプロジェクト
  • B-Cell Non-Hodgkin Lymphoma:開発が中止された製品
  • B-Cell Non-Hodgkin Lymphoma:製品開発のマイルストーン
  • 付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7687IDB

Summary

Global Markets Direct's, 'B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2016', provides an overview of the B-Cell Non-Hodgkin Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for B-Cell Non-Hodgkin Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for B-Cell Non-Hodgkin Lymphoma and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of B-Cell Non-Hodgkin Lymphoma
  • The report reviews pipeline therapeutics for B-Cell Non-Hodgkin Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved B-Cell Non-Hodgkin Lymphoma therapeutics and enlists all their major and minor projects
  • The report assesses B-Cell Non-Hodgkin Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for B-Cell Non-Hodgkin Lymphoma

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for B-Cell Non-Hodgkin Lymphoma
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding B-Cell Non-Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • B-Cell Non-Hodgkin Lymphoma Overview
  • Therapeutics Development
  • B-Cell Non-Hodgkin Lymphoma - Therapeutics under Development by Companies
  • B-Cell Non-Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes
  • B-Cell Non-Hodgkin Lymphoma - Pipeline Products Glance
  • B-Cell Non-Hodgkin Lymphoma - Products under Development by Companies
  • B-Cell Non-Hodgkin Lymphoma - Products under Investigation by Universities/Institutes
  • B-Cell Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development
  • B-Cell Non-Hodgkin Lymphoma - Therapeutics Assessment
  • Drug Profiles
  • B-Cell Non-Hodgkin Lymphoma - Recent Pipeline Updates
  • B-Cell Non-Hodgkin Lymphoma - Dormant Projects
  • B-Cell Non-Hodgkin Lymphoma - Discontinued Products
  • B-Cell Non-Hodgkin Lymphoma - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for B-Cell Non-Hodgkin Lymphoma, H1 2016
  • Number of Products under Development for B-Cell Non-Hodgkin Lymphoma - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Development by Companies, H1 2016 (Contd..7)
  • Number of Products under Development by Companies, H1 2016 (Contd..8)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Development by Companies, H1 2016 (Contd..9)
  • Products under Development by Companies, H1 2016 (Contd..10)
  • Products under Development by Companies, H1 2016 (Contd..11)
  • Products under Development by Companies, H1 2016 (Contd..12)
  • Products under Development by Companies, H1 2016 (Contd..13)
  • Products under Development by Companies, H1 2016 (Contd..14)
  • Products under Development by Companies, H1 2016 (Contd..15)
  • Products under Development by Companies, H1 2016 (Contd..16)
  • Products under Development by Companies, H1 2016 (Contd..17)
  • Products under Development by Companies, H1 2016 (Contd..18)
  • Products under Development by Companies, H1 2016 (Contd..19)
  • Products under Development by Companies, H1 2016 (Contd..20)
  • Products under Development by Companies, H1 2016 (Contd..21)
  • Products under Development by Companies, H1 2016 (Contd..22)
  • Products under Development by Companies, H1 2016 (Contd..23)
  • Products under Development by Companies, H1 2016 (Contd..24)
  • Products under Development by Companies, H1 2016 (Contd..25)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by AB Science SA, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by ADC Therapeutics Sarl, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Affimed Therapeutics AG, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Altor BioScience Corporation, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Amgen Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by arGEN-X BV, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Ariad Pharmaceuticals, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Arrien Pharmaceuticals, LLC, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Arvinas, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Astellas Pharma Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Astex Pharmaceuticals, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by AstraZeneca Plc, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Aurigene Discovery Technologies Limited, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Bayer AG, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by BeiGene, Ltd., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by BIND Therapeutics, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Bio-Path Holdings, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Biocon Limited, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Biogenomics Limited, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Biothera, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Bluebird bio, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Calithera Biosciences, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Celgene Corporation, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Cell>Point, L.L.C., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Celldex Therapeutics, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Celltrion, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Coherus BioSciences, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by CTI BioPharma Corp., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Curis, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Dynavax Technologies Corporation, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by eFFECTOR Therapeutics, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Eisai Co., Ltd., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Eli Lilly and Company, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by EpiZyme, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Erytech Pharma SA, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Genentech, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Genor BioPharma Co., Ltd., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Genosco, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by GlaxoSmithKline Plc, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Hutchison MediPharma Limited, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Idera Pharmaceuticals, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by IGF Oncology, LLC., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Immune Design Corp., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by ImmunoGen, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Immunomedics, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Immunovaccine, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Incyte Corporation, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Inflection Biosciences Limited, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by JHL Biotech, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Johnson & Johnson, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Juno Therapeutics Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Karus Therapeutics Limited, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Kite Pharma, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Les Laboratoires Servier SAS, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by LFB S.A., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Mabion SA, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by mAbxience S.A., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by MedImmune, LLC, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Medivation, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by MEI Pharma, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Merck & Co., Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Merck KGaA, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Mirati Therapeutics Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Mirna Therapeutics, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Molecular Templates Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Molplex Ltd., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by MorphoSys AG, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Neumedicines Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Nimbus Therapeutics, LLC, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Nordic Nanovector ASA, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Novartis AG, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by NovImmune SA, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Onconova Therapeutics, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by OXIS International, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Pfizer Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Philogen S.p.A., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by ProNAi Therapeutics, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by RedHill Biopharma Ltd., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Respiratorius AB, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Rhizen Pharmaceuticals S.A., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Sandoz International GmbH, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Sanofi, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Selvita S.A., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Sorrento Therapeutics, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Stemline Therapeutics, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Takara Bio Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by TG Therapeutics, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by The International Biotechnology Center (IBC) Generium, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Theravectys SA, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by United BioPharma, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Unum Therapeutics, Inc., H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Pipeline by Vivolux AB, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • B-Cell Non-Hodgkin Lymphoma Therapeutics - Recent Pipeline Updates, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Dormant Projects, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..1), H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..2), H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..3), H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..4), H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..5), H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..6), H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..7), H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..8), H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..9), H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..10), H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..11), H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..12), H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Discontinued Products, H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Discontinued Products (Contd..1), H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Discontinued Products (Contd..2), H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Discontinued Products (Contd..3), H1 2016
  • B-Cell Non-Hodgkin Lymphoma - Discontinued Products (Contd..4), H1 2016

List of Figures

  • Number of Products under Development for B-Cell Non-Hodgkin Lymphoma, H1 2016
  • Number of Products under Development for B-Cell Non-Hodgkin Lymphoma - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top